ES2157993T3 - Benzoilguanidinas, su preparacion y su uso en medicamentos. - Google Patents

Benzoilguanidinas, su preparacion y su uso en medicamentos.

Info

Publication number
ES2157993T3
ES2157993T3 ES94931019T ES94931019T ES2157993T3 ES 2157993 T3 ES2157993 T3 ES 2157993T3 ES 94931019 T ES94931019 T ES 94931019T ES 94931019 T ES94931019 T ES 94931019T ES 2157993 T3 ES2157993 T3 ES 2157993T3
Authority
ES
Spain
Prior art keywords
pct
benzoilguanidinas
medicines
preparation
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94931019T
Other languages
English (en)
Inventor
Otto Roos
Georg Speck
Walter Losel
Dietrich Arndts
Wolf-Dietrich Bechtel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Application granted granted Critical
Publication of ES2157993T3 publication Critical patent/ES2157993T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LOS NUEVOS COMPUESTOS DE FORMULA (I), QUE SE EXPLICAN EN LA DESCRIPCION, SE OBTIENEN POR PROCEDIMIENTOS CONVENCIONALES, Y SE PUEDEN UTILIZAR COMO MEDICAMENTOS.
ES94931019T 1993-11-04 1994-10-31 Benzoilguanidinas, su preparacion y su uso en medicamentos. Expired - Lifetime ES2157993T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4337611A DE4337611A1 (de) 1993-11-04 1993-11-04 Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln

Publications (1)

Publication Number Publication Date
ES2157993T3 true ES2157993T3 (es) 2001-09-01

Family

ID=6501758

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94931019T Expired - Lifetime ES2157993T3 (es) 1993-11-04 1994-10-31 Benzoilguanidinas, su preparacion y su uso en medicamentos.

Country Status (20)

Country Link
US (1) US5783576A (es)
EP (1) EP0733046B1 (es)
JP (1) JPH09504535A (es)
KR (1) KR100359676B1 (es)
CN (1) CN1056609C (es)
AT (1) ATE202563T1 (es)
AU (1) AU687911B2 (es)
CA (1) CA2175838A1 (es)
CO (1) CO4290417A1 (es)
DE (2) DE4337611A1 (es)
DK (1) DK0733046T3 (es)
ES (1) ES2157993T3 (es)
GR (1) GR3036642T3 (es)
NZ (1) NZ274849A (es)
PL (1) PL180302B1 (es)
PT (1) PT733046E (es)
RU (1) RU2136659C1 (es)
TW (1) TW400319B (es)
WO (1) WO1995012584A1 (es)
ZA (1) ZA948670B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
ES2224620T3 (es) * 1998-03-23 2005-03-01 Aventis Pharmaceuticals Inc. Derivados de piperidinilo y n-aminopiperidinilo.
US6239279B1 (en) * 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
AU4952700A (en) 1999-06-03 2000-12-28 Takeda Chemical Industries Ltd. Pernasal preparations
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
CA2482991A1 (en) * 2002-04-19 2003-10-30 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof
WO2004022562A1 (en) * 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
US7160885B2 (en) * 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
WO2005014599A1 (en) * 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US20060183746A1 (en) * 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) * 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US7259164B2 (en) * 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
AU2004276341B2 (en) 2003-09-23 2011-04-14 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
TWI378925B (en) * 2005-01-14 2012-12-11 Gilead Connenticut Inc Certain substituted ureas as modulators of kinase activity
WO2007024294A2 (en) * 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
WO2007028051A2 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
NZ587039A (en) 2008-02-13 2013-01-25 Gilead Connecticut Inc 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
KR101745732B1 (ko) 2008-12-08 2017-06-12 질레드 코네티컷 인코포레이티드 이미다조피라진 ｓｙｋ 억제제
KR101743784B1 (ko) * 2008-12-08 2017-06-05 질레드 코네티컷 인코포레이티드 이미다조피라진 ｓｙｋ 억제제
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
ES2530449T3 (es) 2010-03-11 2015-03-02 Gilead Connecticut Inc Inhibidores de Syk de imidazopiridinas
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
SG11201600378SA (en) 2013-07-30 2016-02-26 Gilead Connecticut Inc Formulation of syk inhibitors
US9687492B2 (en) 2013-12-04 2017-06-27 Gilead Sciences, Inc. Methods for treating cancers
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
CA2955180A1 (en) 2014-07-14 2016-01-21 Gilead Sciences, Inc. Combinations comprising entospletinib and a vinca-alkaloid for treating cancers
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
WO2020172431A1 (en) 2019-02-22 2020-08-27 Gilead Sciences, Inc. Solid forms of condensed pyrazines as syk inhibitors
AR127646A1 (es) 2021-11-12 2024-02-14 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
WO2024086790A1 (en) * 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953476A (en) * 1971-12-27 1976-04-27 Merck & Co., Inc. 3-Amino-5-sulfonylbenzoic acids
SU1114021A1 (ru) * 1982-11-11 1995-12-20 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 4-метоксибензилгуанидин или его сернокислая соль, оказывающие ингибирующее действие на моноаминоксидазу мозга
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
EP0556674B1 (de) * 1992-02-15 1996-06-19 Hoechst Aktiengesellschaft 3,5-Substituierte Benzoylguanidine, mit antiarrythmischer Wirkung und inhibierender Wirkung auf die Proliferationen von Zellen
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
DK0589336T3 (da) * 1992-09-22 1997-06-16 Hoechst Ag Benzylguanidiner, fremgangsmåde til deres fremstilling samt deres anvendelse som antiarytmetika
EP0603650B1 (de) * 1992-12-16 1997-04-02 Hoechst Aktiengesellschaft 3,5-Substituierte Aminobenzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
EP0733046B1 (de) 2001-06-27
CA2175838A1 (en) 1995-05-11
WO1995012584A1 (de) 1995-05-11
TW400319B (en) 2000-08-01
PL180302B1 (pl) 2001-01-31
KR100359676B1 (ko) 2003-04-16
CN1134146A (zh) 1996-10-23
DK0733046T3 (da) 2001-09-03
ZA948670B (en) 1995-07-04
KR960705789A (ko) 1996-11-08
US5783576A (en) 1998-07-21
PL314188A1 (en) 1996-09-02
CN1056609C (zh) 2000-09-20
DE4337611A1 (de) 1995-05-11
AU687911B2 (en) 1998-03-05
CO4290417A1 (es) 1996-04-17
HK1010722A1 (en) 1999-06-25
ATE202563T1 (de) 2001-07-15
NZ274849A (en) 1998-08-26
DE59409794D1 (de) 2001-08-02
EP0733046A1 (de) 1996-09-25
RU2136659C1 (ru) 1999-09-10
JPH09504535A (ja) 1997-05-06
AU7993794A (en) 1995-05-23
GR3036642T3 (en) 2001-12-31
PT733046E (pt) 2001-10-30

Similar Documents

Publication Publication Date Title
CO4290417A1 (es) Nuevas benzoilguanidinas como medicamentos y su preparacion .
BR9407239A (pt) Azadioxacicloalquenos substituídos
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
NO306346B1 (no) N-substituerte azabicykloalkanderivater, anvendelse derav og farmasöytisk preparat
ATE169317T1 (de) Pyridobismidazole enthaltendes rigid-rod-polymer
BR9611175B1 (pt) compostos e composiÇÕes farmacÊuticas.
BR0016227A (pt) Derivados de adamantano
ES2102475T3 (es) Nuevas alquil-amidas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
IL96636A0 (en) Piperidine derivatives and pharmaceutical compositions containing them
KR960703863A (ko) 암 치료용 신규 비스-나프탈이미드(New Bis-naphthalimides for the Treatment of Cancer)
UA48958C2 (uk) 9-o-оксимові похідні еритроміцину а та фармацевтична композиція на їх основі
NO306400B1 (no) N-substituerte azabicykloheptan-derivater, anvendelse derav og farmasöytisk preparat
DK0559690T3 (da) 8-en-19,11Beta-broholdige steroider, deres fremstilling og farmaceutiske præparater, som indeholder dem
DK0731801T3 (da) Substituerede aminoaylkylaminopyridiner
SE9401596D0 (sv) New compounds

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 733046

Country of ref document: ES